loader2
Partner With Us NRI

Company details

103.50
103.50
83.05
190.00
6M Return -13.03%
1Y Return -36.99%
Mkt Cap.(Cr) 65.33
Volume 1,500
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 1,500

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 23.92 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,806.36 -39,994.59
LAST 3M 79,235.45 -52,306.79
LAST 6M 143,739.24 -201,556.99
LAST 12M 206,053.08 -176,593.86
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
150
69%
37.8942
8.62%
4.42%
Description
  • Vanta Bioscience Limited was originally incorporated as a private limited company on 29th April 2016 with the name `Vanta Bioscience Private Limited`. The Company was converted into a public limited company and consequently, the name of the Company was changed to `Vanta Bioscience Limited` on 17th March 2017. The Promoters of the Company are Mohan Krishna Mulakala, Dopesh Raja Mulakala, Dr. Vyasmurti Madhavrao Shingatgeri, Dr. Soumya Simhadri, Shravan Chintapatla, Karishma Mulakala, Sajan Kiran Mulakala, Pradeep Chowdary and Dr. Chandrasekhar Rao Simhadri. Vanta Bioscience(VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. VBS entered into an asset transfer agreement dated February 18, 2016 with Kemin Industries South Asia Private Limited, Chennai for the purchase of fully operational toxicology facility Vanta Bioscience` situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai. The Company has taken possession of the said preclinical CRO facility at Gummidipundi, Chennai and has commenced commercial operations thereat from April 1, 2017. Currently the company is mainly doing previous pending research work and are also getting new work from existing clients of Vanta Bioscience` erstwhile division of Kemin Industries South Asia Private Limited. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. The data generated from these studies are submitted to regulatory agencies worldwide before they are put in use for the consumption of domestic animals and human being. In addition, VBS also conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.

Read More

Registered Address

No.02/G/308/G Umajay Complex, Rasoolpura Secunderabad, Hyderabad, Telangana, 500003

Tel : 91-40-66575454
Email : info:vantabio.com
Website : http://www.vantabio.com

Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1500
BSE Code : 540729
NSE Code :
Book Closure Date (Month) :
BSE Group : M
ISIN : INE695X01011

ICICIdirect Vanta Bioscience Ltd FAQ

You can buy Vanta Bioscience Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Vanta Bioscience Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of Vanta Bioscience Ltd was ₹ 103.50.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of Vanta Bioscience Ltd stood at ₹ 65.33.
The latest PE ratio of Vanta Bioscience Ltd as of May 20, 2022 04:01 PM is 150
The latest PB ratio of Vanta Bioscience Ltd as of May 20, 2022 04:01 PM is 0.37
The 52-week high of Vanta Bioscience Ltd is ₹ 190.00 while the 52-week low is ₹ 83.05 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE